Search Results
-
Post
Novocure Announces 18 Presentations on Tumor Treating Fields at SNO 2015 Including New Analyses of the EF-14 Newly Diagnosed Glioblastoma Clinical Trial Data
...GBM, and support Novocure’s goal to establish Optune as a standard of care for newly diagnosed glioblastoma. “The EF-14 phase 3 data show that GBM patients who use Optune in...
-
Post
FDA Approves the NovoTTF-100LTM System in Combination with Chemotherapy for the Treatment of Malignant Pleural Mesothelioma
...Optune ineffective. Use of the NovoTTF-100L System for MPM or Optune for GBM together with implanted electronic devices has not been tested and may lead to malfunctioning of the implanted...
-
Post
Novocure Reports Second Quarter 2018 Financial Results and Provides Company Update
...treat patients with Optune for a patient not previously on Optune. Orders to renew or extend treatment are not included in this total. “In the second quarter of 2018, Novocure...
-
Post
Novocure Receives CE Mark for NovoTTF-100L™ System
...get pregnant, as the safety and effectiveness of NovoTTF-100L/Optune Lua in these populations have not been established. Please visit www.optunelua.com to see NovoTTF-100L/Optune Lua Instructions For Use (IFU) for complete...
-
Post
Novocure Reports Fourth Quarter and Full Year 2018 Financial Results and Provides Company Update
...is received from a physician certified to treat patients with Optune for a patient not previously on Optune. Orders to renew or extend treatment are not included in this total....
-
Post
Novocure Announces Fourth Quarter and Full Year 2018 Operating Statistics, Preliminary Net Revenues and Provides Company Update
...Optune for a patient not previously on Optune. Orders to renew or extend treatment are not included in this total. (3) The preliminary, unaudited results described in this press release...
-
Post
Novocure Reports First Quarter 2018 Financial Results and Provides Company Update
...(2) A “prescription received” is a commercial order for Optune that is received from a physician certified to treat patients with Optune for a patient not previously on Optune. Orders...
-
Post
Novocure Reports Third Quarter 2018 Financial Results and Provides Company Update
...order for Optune that is received from a physician certified to treat patients with Optune for a patient not previously on Optune. Orders to renew or extend treatment are not...
-
Post
Novocure Announces Preliminary 2015 Operating Statistics
...quarter of 2015 was marked by substantial growth versus the prior quarter driven primarily by the FDA approval for Optune in newly diagnosed glioblastoma on October 5, 2015. This growth...
-
Post
Novocure Reports Second Quarter 2019 Financial Results and Provides Company Update
...commercial order for Optune that is received from a physician certified to treat patients with Optune for a patient not previously on Optune. Orders to renew or extend treatment are...